NovoCure (STU:038) Valuation Rank


STU:038 NovoCure Ltd STU:038
70 GF Score
Price €15.13
GF Value €16.30
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is NovoCure Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NovoCure Valuation Rank Related Terms

STU:038
70GF Score
NovoCure Ltd STU:038
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NovoCure (STU:038) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of €15.13 is trading 7.2% below its estimated GF Value™ of €16.30. GuruFocus considers NovoCure to be Fairly Valued.

Key valuation signals for STU:038:

  • Valuation Rank:
  • GF Value™: €16.30 vs. price of €15.13 (7.2% below fair value)
  • GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the STU:038 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
70GF Score

Get the complete analysis for STU:038

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.13
Price
€16.30
GF Value